NASDAQ$CRMD
CorMedix Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
CorMedix reported first quarter 2024 financial results and provided a business update.
CorMedix reported a net loss of $14.5 million for the first quarter of 2024, driven by an increase in operating expenses, partially offset by the sale of New Jersey NOLs for $1.4 million. The company's SG&A expenses increased significantly due to the hiring of sales force, medical affairs, and marketing personnel, while R&D expenses decreased.
- CorMedix officially transitioned to a commercial stage organization.
- Meaningful interest received in scheduling DefenCath for formulary review at various institutions.
- Focus on upcoming outpatient launch and engaging with customers regarding DefenCath as a preventative measure.
- Commercial launch of DefenCath in outpatient settings is anticipated in July 2024.
Headline financials
Revenue & EPS history
CorMedix · Revenue · Quarterly
$0
Forward guidance
CorMedix believes that it has sufficient resources to fund operations for at least twelve months from the issuance of the Company’s Quarterly Report on Form 10-Q.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+12.4%
Avg return
30 days after
43%
20 / 47 earnings
Positive
+31.1%
Q3 2022
Best reaction
-31.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +4.4% | +16.7% | |
| Q4 2025 | -11.7% | -5.6% | -1.0% | |
| Q3 2025 | +2.1% | -10.8% | +2.7% | |
| Q1 2025 | +23.6% | +29.1% | +46.0% | |
| Q4 2024 | -31.8% | +13.8% | +98.2% | |
| Q3 2024 | -22.4% | -26.1% | -24.0% | |
| Q2 2024 | +27.0% | +36.5% | +83.9% | |
| Q1 2024 | -9.5% | -6.7% | -9.6% | |
| Q4 2023 | +10.8% | +8.2% | +81.5% | |
| Q3 2023 | +7.1% | +28.9% | +10.9% | |
| Q2 2023 | +6.1% | +7.3% | -8.5% | |
| Q1 2023 | -13.9% | -1.5% | +5.2% | |
| Q4 2022 | +13.1% | +16.4% | +35.0% | |
| Q3 2022 | +31.1% | +30.4% | +33.6% | |
| Q2 2022 | +22.8% | +26.6% | +10.1% | |
| Q1 2022 | +7.6% | +25.7% | -3.3% | |
| Q4 2021 | +3.4% | -1.4% | -37.6% | |
| Q3 2021 | +0.4% | -0.4% | -6.0% | |
| Q2 2021 | +7.1% | +4.2% | -21.7% | |
| Q1 2021 | -23.1% | -16.9% | +4.6% | |
| Q4 2020 | +15.0% | +16.1% | -1.4% | |
| Q3 2020 | -0.9% | +5.7% | +61.0% | |
| Q2 2020 | -0.5% | +5.6% | +10.0% | |
| Q1 2020 | -6.9% | -2.7% | +54.2% | |
| Q4 2019 | -22.5% | -31.3% | -3.8% | |
| Q3 2019 | +6.1% | +28.2% | +25.8% | |
| Q2 2019 | -2.8% | -0.6% | -3.6% | |
| Q1 2019 | -7.7% | -0.4% | +8.7% | |
| Q4 2018 | -1.6% | -14.6% | -0.5% | |
| Q3 2018 | -15.5% | +9.1% | +27.3% | |
| Q2 2018 | -21.7% | -25.0% | -1.7% | |
| Q1 2018 | -5.0% | -5.0% | +60.0% | |
| Q4 2017 | -19.4% | -32.3% | -32.3% | |
| Q3 2017 | +3.8% | -9.4% | +5.7% | |
| Q2 2017 | -5.4% | -2.7% | +16.2% | |
| Q1 2017 | -5.8% | -5.8% | -15.4% | |
| Q4 2016 | -12.2% | -22.0% | -40.5% | |
| Q3 2016 | -18.6% | -22.1% | -23.0% | |
| Q2 2016 | -7.1% | -8.4% | +18.8% | |
| Q1 2016 | -11.7% | — | — | |
| Q4 2015 | -5.2% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | — | — | — | |
| Q2 2014 | +5.9% | — | — | |
| Q2 2013 | +24.4% | — | — | |
| Q4 2013 | -1.2% | — | — | |
| Q2 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro